Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 16 March 2017 — Link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office of A$974,908 for […]
Clinical data collected from final patient, completing trial • Company plans PMA submission upon receipt of shelf-life stability data • PMA decision anticipated during the 2nd calendar quarter of 2018 Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 7 March 2017 — link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused […]
U.S. FDA Approves increased Compassionate Use Patient Cases and Sites for ReCell® in Life-Threatening Injuries • Up to 48 patients can now be treated at 15 US burnscenters • Increased use of ReCell® device US surgeons under the Compassionate Use dispensations • Latest FDA approval separate to approval earlier in the month for Continued […]
CEO Shareholder Letter and Quarterly Report Dear Shareholder, link here As we conclude another quarter, it’s appropriate that I bring you, our owners, up-to-date on the progress Avita has made in recent months. US Approval Program Update The big goal that our team is working towards is entry to the US market, and I am […]
Thursday, November 10, 2016 5:27 pm EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “AmpliPhi has made tremendous progress this quarter, demonstrated the announcement of topline data from clinical trials of both of our lead development programs, including the first U.S.-based trial of AB-SA01” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]
CATEGORY: Featured Thursday, November 17, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics, today announced the pricing of an underwritten public offering of 5,335,000 shares of its […]
Digital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. – link here Background Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. Boasting the broadest range of “smart” medication sensors for respiratory medications globally, […]
Digital monitoring device proven to increase adherence and reduce hospital visits – link here The National Institute for Clinical Excellence (NICE) has recognised digital platform Smartinhaler as the most effective means of improving asthma medication adherence in new guidance. The Medtech Innovation Briefing – designed to accelerate NHS access to innovation in new treatments and […]
23 February 2017: Adherium Limited (ASX : ADR), link here a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe. Erin Wansbrough will lead Adherium’s partnering and market […]
CATEGORY: Featured Thursday, February 23, 2017 6:50 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In 2017, AmpliPhi plans to initiate phage therapy studies in several patient groups, which we expect will mark a key inflection point for AmpliPhi and the phage therapy field” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: